ID: h-gwas-plcg2-protective-mimicry-5dee99f5
Hypothesis
Calibrated PLCG2 activation can reproduce the protective rs72824905 microglial state in AD
The ad_genetic_risk_loci dataset identifies PLCG2 rs72824905 as a rare protective AD variant with a strong protective odds-ratio proxy.
EvidenceStrong (68%)📖 0 cit🗣 1 debates✓ 7 support✗ 1 oppose
🧪 Overview
The ad_genetic_risk_loci dataset identifies PLCG2 rs72824905 as a rare protective AD variant with a strong protective odds-ratio proxy. The notebook's Enrichr and GTEx analysis places PLCG2 in a microglial immune signaling module with actionable phospholipase biology. Hypothesis: partial, pathway-biased PLCG2 activation can increase microglial plaque and debris clearance while avoiding broad inflammatory gain-of-function toxicity.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["SYK Activation<br/>Downstream of TYROBP"]
B["PLCG2 Phosphorylation<br/>Tyr753/Tyr759"]
C["PIP2 Hydrolysis<br/>IP3 + DAG Generation"]
D["IP3 Receptor<br/>ER Ca2+ Release"]
E["DAG/PKC Activation<br/>Cytoskeletal Remodeling"]
F["Calcium-Dependent<br/>Phagocytic Activity"]
G["Amyloid-beta/Tau<br/>Phagocytosis"]
H["P522R Variant<br/>Enhanced PLCG2 Activity"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F --> G
H -.->|"protective"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8⚖️ Evidence
⚖️ Evidence Matrix7 supports1 contradicts
Supports
PLCG2 rs72824905 is a protective rare variant in AD with OR around 0.32 in the curated notes.
dataset:ad_genetic_risk_loci
Supports
PLCG2 ranked high on druggability due to protective human genetics, phospholipase biology, and immune-cell expression context.
notebook:gwas-ad-risk-loci-analysis
Supports
Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer's disease.
Supports
The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model.
Supports
PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology.
Supports
Alzheimer's disease-associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell-derived microglia-like cells.
Supports
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.
Contradicts
Protective genetics do not define the safe activation window; inflammatory gain-of-function alleles create toxicity risk.
notebook:gwas-ad-risk-loci-analysis
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — PLCG2
No curated PDB or AlphaFold mapping for PLCG2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for PLCG2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PLCG2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0240
Events (7d)
1
Price History
▼16.2%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we perform single-nucleus RNA-seq on post-mortem prefrontal cortex tissue from heterozygous rs72824905 carriers (n≥12) vs age-matched non-carrier AD cases (n≥24) from the AMP-AD or Religious Orders | ≥1.5-fold upregulation of microglial clearance gene module; ≥25% lower neuritic plaque density; no elevation of type I interferon response genes | — no observation — | pending | 0.55 |
| IF we administer a selective PLCG2 partial agonist (targeting the C-terminal SH3 domain to bias toward PIP2 hydrolysis over inflammatory signaling) to 6-month-old 5xFAD mice via continuous subcutaneou | ≥30% reduction in cortical amyloid plaque burden; ≥2-fold increase in microglial phagocytic marker CD68; stable or reduced pro-inflammatory cytokines | — no observation — | pending | 0.60 |
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF we administer a selective PLCG2 partial agonist (targeting the C-terminal SH3 domain to bias toward PIP2 hydrolysis over inflammatory signaling) to 6-month-old 5xFAD mice via continuous subcutaneous infusion for 8 weeks, THEN cortical amyloid plaque density will decrease by ≥30% (measured by [11C
Predicted outcome: ≥30% reduction in cortical amyloid plaque burden; ≥2-fold increase in microglial phagocytic marker CD68; stable or reduced pro-inflammatory cytokines
Falsification: Plaque density does not decrease by at least 20%; or IL-1β/TNF-α increase >50%; or mouse survival/body weight decreases significantly indicating toxicity
pendingconf 55%
IF we perform single-nucleus RNA-seq on post-mortem prefrontal cortex tissue from heterozygous rs72824905 carriers (n≥12) vs age-matched non-carrier AD cases (n≥24) from the AMP-AD or Religious Orders Study cohort, THEN microglial nuclei from carriers will show significantly increased expression of
Predicted outcome: ≥1.5-fold upregulation of microglial clearance gene module; ≥25% lower neuritic plaque density; no elevation of type I interferon response genes
Falsification: No significant difference in clearance gene expression; instead, increased expression of inflammatory genes (CXCL10, ISG15); or plaque burden equal or higher in carriers
▸Metadatasource: v1_phase_c_backfill · origin_type: forge_notebook
| source | v1_phase_c_backfill |
| origin_type | forge_notebook |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.